[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_102":103},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":31,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":-5,"_48":49,"_50":-5,"_51":-5,"_52":53,"_54":55,"_56":57,"_58":42,"_59":42,"_60":61,"_62":42,"_63":64},"id","mgr70hyzo8rdme6nsqhxf79cl","revision",2,"title","BridgeBio宣布FDA接受infigratinib NDA并进入优先审查","originalTitle","8-K - BridgeBio Pharma, Inc. (0001743881) (Filer)","summary","BridgeBio Pharma, Inc.于2026年10月6日发布新闻稿，宣布其口服药物infigratinib的NDA已被FDA接受并进入优先审查，用于治疗儿童软骨发育不全症。该新闻稿作为8-K文件的附件99.1提交。","reason","BridgeBio Pharma的口服药物infigratinib获得FDA接受并进入优先审查，可能影响其儿童软骨发育不全症治疗产品的上市进程。","source",{"_12":93,"_94":95,"_9":96,"_97":42,"_98":99,"_100":101},"links",{"_90":91,"_78":92},"publishedAt","2026-10-13T10:01:35.000Z","discoveredAt","2026-10-13T10:07:10.787Z","timelineAt","category","ai-products","tags",[84,85,86,87,88,89],"stockSymbols",[83],"score",62,"selected",true,"channel","news","story",{"_73":74,"_16":75},"x","readingMode","full","author","language","body",{"_64":77,"_78":-5,"_79":80,"_81":82},"outline",[],"relatedStories",[76],"indexable","markdownAvailable","group",{"_65":66,"_45":67,"_68":69,"_70":71,"_72":71},"hasTranslation","bodyLanguage","zh","factId","fWFK1Ch5kv34",{"_73":74,"_16":75},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","e971a394-a465-4b5b-82ab-fc8d2cc9e6f5","BridgeBio infigratinib获FDA优先审查",{"_73":74,"_16":75},"

UNITED STATES\n

\n SECURITIES AND EXCHANGE COMMISSION\n

\n WASHINGTON, D.C. 20549\n

FORM 8-K

CURRENT REPORT\n

\n Pursuant to Section 13 or 15(d)\n

\n of the Securities Exchange Act of 1934\n

Date of Report (Date of earliest event reported): October 6, 2026

BridgeBio Pharma, Inc.

\n (Exact name of registrant as specified in its charter)\n

Delaware

001-38959

84-1850815

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3160 Porter Drive, Suite 250

Palo Alto, CA

94304

(Address of principal executive offices)

(Zip Code)

(650) 391-9740

\n (Registrant’s telephone number, including area code)\n

\n Not Applicable\n

\n (Former name or former address, if changed since last report)\n

\n Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):\n

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

\n Securities registered pursuant to Section 12(b) of the Act:\n


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock	BBIO	The Nasdaq Global Select Market

\n Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).\n

Emerging growth company ☐

\n If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n

\n Item 8.01.\n

\n Other Events. \n

\n On October 6, 2026, BridgeBio Pharma, Inc. issued a press release titled “BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n

\n Item 9.01.\n

\n Financial Statements and Exhibits.\n

\n (d) Exhibits.\n

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n


\n \n Exhibit\n \n
\n \n No.\n \n	\n \n Description\n \n

\n \n 99.1\n \n	\n \n Press release titled “BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia”\n \n

\n \n 104\n \n	\n \n 封面页交互式数据文件（嵌入在内联 XBRL 文档中）\n \n

\n 签名\n

\n 根据 1934 年证券交易法的要求，注册人已正式授权本报告由以下签署人代表其签署。\n

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n


\n	\n \n BridgeBio Pharma, Inc.\n \n
\n \n	\n \n
\n \n 日期：2026 年 10 月 13 日\n \n	\n \n /s/ Thomas Trimarchi\n \n
\n	\n \n Thomas Trimarchi\n \n
\n	\n \n 总裁兼首席财务官\n \n

","original","zhKind","translation","complete",false,"BBIO","公司与财报","行业与主题","政策与监管","观点与解读","其他","宏观与美联储","aihot","/items/mgr70hyzo8rdme6nsqhxf79cl","https://www.sec.gov/Archives/edgar/data/1743881/000114036126039334/0001140361-26-039334-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792108800&sig=e4adf00b596060d2","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792108800&sig=208b33ec2756b0ea 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792108800&sig=786fcd6a5ff8379c 96w","changelogVersion","2026-10-01T08:00"]